Solvonis Therapeutics PLC (LSE:SVNS) CEO Anthony Tennyson talked about the company's innovative approach to treating alcohol use disorder (AUD) and post-traumatic stress disorder (PTSD) at the Proactive One2One Investor Forum.
Solvonis is advancing a ketamine-assisted therapy program currently in Phase 3, focused on severe AUD. Tennyson highlighted that in their Phase 2 trial, patients receiving the active treatment achieved “86% sobriety in the six months post-treatment”—a major leap from the 2% baseline.
Solvonis is partnering with the UK Department of Health and conducting trials within the NHS, aiming to address a condition that affects 14 million people across key Western markets. The company's model is capital efficient, with the ongoing Phase 3 trial costing just £800,000. Tennyson underscored the commercial opportunity, noting a potential market of “200 billion sterling in annual direct medical costs” tied to AUD and pointing to a significant valuation gap with peers in the US.
Their dual-track strategy includes a second program for the larger US market using esketamine, with licensing talks underway. Solvonis does not intend to commercialise drugs directly but will seek licensing deals to generate revenue via royalties and milestone payments.
#SolvonisTherapeutics #AlcoholUseDisorder #KetamineTherapy #PTSDTreatment #BiotechStocks #MentalHealthInnovation #PharmaceuticalResearch #Phase3ClinicalTrial #AddictionTreatment #HealthcareInnovation
